Conference item icon

Conference item

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study

Publication status:
Published
Peer review status:
Reviewed (other)

Actions


Access Document


Publisher copy:
10.1002/art.40700

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Role:
Author
ORCID:
0000-0002-4756-663X
Expand authors...
Publisher:
Wiley Publisher's website
Journal:
Arthritis and Rheumatology Journal website
Volume:
70
Issue:
S9
Article number:
2565
Host title:
Arthritis and Rheumatology
Publication date:
2018-10-15
Acceptance date:
2018-10-15
DOI:
EISSN:
2326-5205
ISSN:
2326-5191
Source identifiers:
939157
Keywords:
Pubs id:
pubs:939157
UUID:
uuid:153b3b9a-a9c9-4cf1-af0e-3062b39e92f0
Local pid:
pubs:939157
Deposit date:
2019-06-06

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP